Inhibition of IκB Kinase β (IKKβ) and Anti-diabetic Effect of SA51 


Vol. 34,  No. 8, pp. 2487-2490, Aug.  2013
10.5012/bkcs.2013.34.8.2487


PDF
  Tumbnail

  Abstract

SA51, a medium potency inhibitor of protein tyrosine phosphatase 1B (PTP1B), was identified to be a potent inhibitor of IκB kinase β (IKKβ). Consistent with this, SA51 prevented lipopolysaccharide (LPS)-induced breakdown of IκBα in macrophages. The effects of SA51 in mice were compared with those of structurally related compounds, SA18 and SA32, which were previously reported as inhibitors of both enzymes - less potent against IKKβ but more potent against PTP1B compared to SA51. SA51 improved glucose tolerance and lipid parameters in mice, consistent with the results reported for IKKβ+/− mice. In contrast, SA18 and SA32 showed anti-obesity effects without anti-diabetic effects. Collectively, the effects of SA51 could be due largely to the inhibition of IKKβ, whereas SA18 and SA32 may be more likely to inhibit PTP1B, consistent with their relative in vitro inhibitory effects.

  Statistics
Cumulative Counts from November, 2022
Multiple requests among the same browser session are counted as one view. If you mouse over a chart, the values of data points will be shown.


  Cite this article

[IEEE Style]

B. R. Bhattarai, B. Kafle, J. Hwang, I. Han, H. Cho, "Inhibition of IκB Kinase β (IKKβ) and Anti-diabetic Effect of SA51," Bulletin of the Korean Chemical Society, vol. 34, no. 8, pp. 2487-2490, 2013. DOI: 10.5012/bkcs.2013.34.8.2487.

[ACM Style]

Bharat Raj Bhattarai, Bhooshan Kafle, Ji-Sun Hwang, Inn-Oc Han, and Hyeongjin Cho. 2013. Inhibition of IκB Kinase β (IKKβ) and Anti-diabetic Effect of SA51. Bulletin of the Korean Chemical Society, 34, 8, (2013), 2487-2490. DOI: 10.5012/bkcs.2013.34.8.2487.

Search
(IN TITLE, AUTHOR, ABSTRACT,KEYWORDS)

Advanced Search ▼

POPULAR KEYWORDS
(TOP 10 KEYWORDS)

Recent Publications
(LAST 3 YEARS)

ISSN(Print) 0253-2964
ISSN(Online) 1229-5949